Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 10/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.47 |
| ▸ | CDK2 | P24941 | 7/20 | 0.47 |
| ▸ | CCND1 | P24385 | 5/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNH | P51946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524640 | 0.85 | HRH4 (0.42) | IKBKBCCNE1CDK2HRH4 | |
| SCHEMBL84003 | 0.84 | IKBKB (0.49) | IKBKBCCNE1CDK2CCND1CDK6 | |
| SCHEMBL13524608 | 0.83 | IKBKB (0.57) | IKBKBCCNE1CDK2CCND1CDK6 | |
| SCHEMBL12367075 | 0.80 | IKBKB (0.61) | IKBKBCCNE1CDK2CCND1CDK6 | |
| SCHEMBL91469 | 0.80 | CTSK (0.49) | IKBKBCCNE1CDK2CCND1MAPK8 | |
| SCHEMBL14176051 | 0.77 | MAPK8 (0.56) | IKBKBCCNE1CDK2CCND1MAPK8 | |
| SCHEMBL91478 | 0.77 | CTSK (0.58) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL15830033 | 0.76 | MAPK1 (0.62) | MAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL91484 | 0.75 | CTSK (0.60) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL30768109 | 0.75 | CCNE1 (0.49) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | IKBKB 541/4885CCNE1 353/4885CDK2 20/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | IKBKB 345/4885CCNE1 487/4885CDK2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.